Bharat Book Bureau: PharmaPoint: Seasonal Influenza Vaccines France Drug Forecast and Market Analysis
(M2 PressWIRE Via Acquire Media NewsEdge) Summary
"PharmaPoint: Seasonal Influenza Vaccines France Drug Forecast and Market Analysis". Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.
The French influenza vaccine market is valued at approximately $47.8 million in 2012. The projected drivers of sales growth include the growth of the elderly population and introduction of quadrivalent seasonal influenza vaccines. Sanofi is the market leader in France. The French influenza manufacturer controls over a third of the influenza vaccine market in this country, with a portfolio that includes trivalent intramuscular influenza vaccines Vaxigrip and Mutagrip and an intradermal vaccine, Intanza. Sanofi's home field advantage and novel products have enabled it to dominate the French market.
- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in France from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the France seasonal influenza market.
For more information kindly visit : http://www.bharatbook.com/healthcare-market-research-reports/pharmapoint-seasonal-influenza-vaccines-france-drug-forecast-and-market-analysis.html
Contact us at :
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Follow us on twitter: https://twitter.com/researchbook
Follow us on linkedin : http://www.linkedin.com/company/bharat-book-bureau
Our Blog : http://blog.bharatbook.com/
For Live Chat - http://bit.ly/19m3TU4
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.com on the world wide web. Inquiries to email@example.com)).
(c) 2013 M2 COMMUNICATIONS
[ InfoTech Spotlight's Homepage ]